Nasdaq
$3.66▼ 1.48%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $764.8MShares out 2.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.6After-hours26.10.07 06:016-KKey event#●●●#●●●
Inventiva S.A.
Inventiva will present three abstracts detailing preclinical and clinical data for its MASH therapeutic candidate, lanifibranor, at the AASLD The Liver Meeting 2026, scheduled for November 5-9, 2026. The company is currently conducting the Phase 3 NATiV3 clinical trial for lanifibranor, with topline results expected in the fourth quarter of this year.…more
$3.66-1.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28Pre-market26.09.28 20:076-KKey event
Inventiva S.A.
Inventiva reported its financial results for the first half of 2026, disclosing cash and cash equivalents of €166.1 million and short-term deposits of €67.8 million as of June 30, 2026. The company confirmed that patient enrollment for its Phase 3 NATiV3 clinical trial of lanifibranor is complete, with topline results expected in the fourth quarter of 2026.…more
$3.66-1.48%vs prev closeView filingShare - 9.3Pre-market26.09.03 19:006-KKey event
Inventiva S.A.
Inventiva has completed the final 72-week visit for the last patient in its Phase 3 NATiV3 clinical trial of lanifibranor for MASH. The company expects to report topline results in Q4 2026 and anticipates regulatory submission in the first half of 2027, with a potential U.S. launch in 2028 subject to FDA approval.…more
$3.66-1.48%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:05#●●●#●●●
Inventiva to Present MASH Treatment Research at AASLD 2026
Inventiva will present new preclinical and clinical data for its MASH drug candidate, lanifibranor, at the upcoming AASLD The Liver Meeting in November. The company is currently conducting Phase 3 trials with topline results expected in the fourth quarter of this year.…more
$3.66-1.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.28Overnight26.09.28 15:11
●●●●●●●● ●●●●● ●●●●●●
Inventiva reported a loss per share of $0.29 and revenue of $23,251, significantly missing analyst expectations. The company saw a sharp decline in revenue compared to the same period last year, highlighting ongoing financial challenges.…more
$3.66-1.48%vs prev closeShareBenzinga - 9.28Overnight26.09.28 15:00
●●●●●●●● ●●●●● ●●●●●●
Inventiva released its first-half 2026 financial results, highlighting secured funding to support operations through 2027. The company expects to report topline results from its Phase 3 NATiV3 clinical trial for MASH in the fourth quarter of 2026.…more
$3.66-1.48%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report